Omega-3 Polyunsaturated Fatty Acid (Fish Oil) Supplementation and the Prevention of Clinical Cardiovascular Disease: A Science Advisory From the American Heart Association.
Siscovick DS, Barringer TA, Fretts AM, Wu JH, Lichtenstein AH, Costello RBet al.
Circulation · 2017; 135(15):e867-e884
This study evaluates Omega-3 polyunsaturated fatty acid (fish oil) supplements containing eicosapentaenoic acid (EPA) plus docosahexaenoic acid (DHA), typically 1 gram or more per day in relation to Occurrence of clinical cardiovascular disease events such as heart attack, stroke, heart failure hospitalization, or cardiovascular death.
Evidence-Based Research: Omega 3 Inflammation Aha
Key facts at a glance
- DOI
- 10.1161/cir.0000000000000482
- PMID
- 28289069
- PMC
- PMC6903779
- Journal
- Circulation
- Year
- 2017
- Volume
- 135
- Issue
- 15
- Pages
- e867-e884
- Study type
- guideline
- Evidence level
- Ia
- Intervention
- Omega-3 polyunsaturated fatty acid (fish oil) supplements containing eicosapentaenoic acid (EPA) plus docosahexaenoic acid (DHA), typically 1 gram or more per day
- Primary outcome
- Occurrence of clinical cardiovascular disease events such as heart attack, stroke, heart failure hospitalization, or cardiovascular death
- Follow-up
- Varied across trials (typically 1-5 years)
- Funding
- unknown
- Open access
- false
Study Overview
This study examined the effects of Omega-3 polyunsaturated fatty acid (fish oil) supplements containing eicosapentaenoic acid (EPA) plus docosahexaenoic acid (DHA), typically 1 gram or more per day on Occurrence of clinical cardiovascular disease events such as heart attack, stroke, heart failure hospitalization, or cardiovascular death.
Key Findings
The results suggest the intervention has potential clinical benefits.
Clinical Conclusions
See original publication.
Abstract
"This clinical guideline synthesizes evidence on Omega-3 polyunsaturated fatty acid (fish oil) supplements containing eicosapentaenoic acid (EPA) plus docosahexaenoic acid (DHA), typically 1 gram or more per day and Occurrence of clinical cardiovascular disease events such as heart attack, stroke, heart failure hospitalization, or cardiovascular death.
Funding & conflicts of interest
Funding: unknown
COI: None reported for the advisory writing group beyond standard AHA disclosures
Related topics
This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed July 22, 2026. · Read our editorial policy